The 5th Circuit Court of Appeals heard oral arguments on September 9 in Louisiana v. FDA, a case that questions the FDA's regulation of mifepristone, a drug used in medication abortion. The outcome could have broad implications for how the drug is prescribed and dispensed across the United States.
The FDA has long characterized mifepristone as highly safe and effective, but the plaintiffs argue the agency overstepped its authority in regulating it. A ruling against the FDA could impose new restrictions, while a ruling in favor of the agency would likely preserve the current regulatory framework.
Because the case is being decided by a conservative-leaning appeals court, legal observers expect the ruling to be significant regardless of the specific outcome. The decision could also set the stage for further review by the Supreme Court.